summari septemb host investor meet
ew manag includ mike mussallem chairman ceo
scott ullem corpor vice-president cfo mark wilterd vice-president
investor relat overal thought manag sound
posit underli trend busi came away
increas convict ew deliv state target key
takeaway us ew appear well-posit deliv
guidanc manag optimist growth
momentum beyond ep could impact
hedg gain higher tax rate potenti return
med-tech tax ew optimist new indic low risk
bring patient sidelin stronger clinic data
pipelin off-set new futur competit manag
remain optimist opportun transcathet mitral
tricuspid therapi tmtt critic care surgic heart
valv continu grow rais price target
assum ep estim
ew appear well-posit deliv remind
follow earn manag rais sale guidanc
underli growth guidanc
top-end rang tavr sale guidanc move
higher underli growth
expect top-end rang math
show tavr guidanc impli sequenti deceler
underli compani post underli tavr
growth manag said better baromet look
growth vs top end guidanc full
year lastli discuss potenti wareh dynam wherein
clinician wait low risk approv manag believ
might heard anecdot
evid also mention aortic stenosi patient
warehous well report patient die wait list exist
view bottom line manag sound confid
could deliv target
continu follow page
compani data secur llc estim reuter
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
manag optimist growth outlook ew tavr revenu grew
full year guidanc high-end impli growth slightli better closer
manag commentari busi outlook seem suggest posit
momentum sustain beyond especi multi-year ramp expect new
low-risk tavr indic manag continu see tavr market suggest low-
doubl digit compound-annual-growth-rate ew tavr busi gener grow market better beyond
tavr manag note surgic critic care cc busi also continu perform well
low-risk tavr ramp could cannib surgic volum ew believ
patient come sidelin help drive posit growth compani anticip brexit
meaning impact busi overal ew manag optimist futur
opportun beyond tavr
hedg gain tax rate repres potenti headwind ep growth
bottom-lin would highlight two potenti headwind growth next year first fx repres
gross margin tailwind due benefit currenc hedg assum currenc rate
remain rel stabl hedg benefit goe away ew gross margin return
level vs guidanc said manag expect benefit
gross margin next year product mix suppli chain improv second ew tax rate
guidanc manag expect low-end rang includ benefit
new rule relat employe stock option account remain unclear account rule
affect tax rate next year point mid- high-teen reason assumpt
tax rate manag expect invest remain high-teen forese
futur aim increment oper margin improv time current forecast
ep growth consensu forecast due mention factor
ew manag concern return med-tech tax ew manag note
potenti return tax us revenu concern head next year current
suspens med-tech tax due expir end year compani estim
med-tech tax would add sg expens come back gener
heard industri concern return med-tech tax ew manag express concern
possibl ew model assum resumpt med-tech tax
new low risk indic forefront growth stori term low risk approv
tavr busi manag remain cautious optimist near term bullish longer-
term near term biggest question ew today perspect play like
saw bump intermedi risk data growth slow compani
receiv fda approv august manag address dynam cite may certainli
end like perfect analogu indic
snowflak differ competit dynam differ type data present present
intermedi risk data tavr player lead modest boost follow quarter
greater uptick line longer term manag reiter bullish view tavr
commerci market equat low doubl digit compound-annual-growth-rate low risk approv hand
manag believ data carri day expand awar therapi lastli
geograph perspect manag comment tavr acceler seen europ
believ low risk data us impact eu perform even though
indic come sometim
sapien ultra strategi unchang us ew continu leverag sapien deliveri
system short-term longer term howev compani hope find anoth deliveri solut
address risk balloon burst compani deliber pace launch sapien ultra
ensur appropri physician train proctor due design valv system featur
new sheath on-balloon valv design outsid us ew continu expect ultra account
major european tavr sale year-end
ew pleas ncd overal manag believ right thing regard
decis ncd tavr specif patient tend get refer
referr network often whole popul peopl get option get tavr
procedur put number around manag reiter view coupl hundr addit
center would assumpt estim part point addit
one surgeon requir caus patient move system much slower need
surgeon sign procedur
updat tavr competit landscap ew note abt portico tavr could approv
us year-end abt pivot trial compar portico head-to-head ew sapien mdt
corevalv data expect tct transcathet cardiovascular meet
late septemb ew manag note strength third-gener sapien clinic data
sens neither manag invest commun concern upcom
portico data present lotu fda approv earlier year ew believ
compani work establish us footprint ew manag note competitor
disciplin tavr price expect new competitor similarli disciplin
ew see mitral/tricuspid signific market opportun ew first-to-market
mitral regurgit mr space manag confid becom leader field base
view signific market opportun well beyond current sale competitor abt
mitraclip compani view encompass clip band well valv repair
replac ew want first appli transsept ts approach mitral valv replac
believ may offer greater access treatment patient compar transap ta
rout believ close resembl surgic approach addit ew note pascal
technolog adapt tricuspid devic track start go first pivot
trial later year manag believ tricuspid opportun could larger mitral
one analyst day ew size global transcathet mitral tricuspid therapi tmtt
market reach refer estim ww sale abt
mitraclip total grow model ew pascal sale
grow
pace roll-out transcathet mitral therapi may differ us vs eu us
posit coapt trial repres potenti tailwind mitral market help drive market
growth compani continu pace roll pascal europ achiev consist incred
result manag emphas procedur outcom rather sale ramp often focu
new product launch like pascal salesforc often incentiv way compani
purpos pace launch manag believ sale ramp could much meaning
europ mitra-fr studi influenti thu headwind overal
mitral market growth recal mitra-fr show benefit mitraclip function mitral regurgit
mr manag continu expect tmtt sale least
updat pascal pivot mitral clinic studi year-end ew two pivot trial
compar pascal head-to-head abt mitraclip mitral valv repair first studi pascal
clasp iid dmr degen mitral regurgit us pivot studi began expect patient
enrol complet year-end six month follow could see data
although manag would confirm manag note surrog endpoint
function improv use clasp iid trial suffici fda approv
reimburs clasp iif fmr function mitral regurgit us pivot trial track start
later compani give develop timelin note iif take time
patient enrol expect take longer patient optim medic manag
fda requir two-year follow primari endpoint vs follow-up iid
said manag confirm look
earli optim forgotten valv tricuspid regard ew tricuspid therapi thing
watch view pascal tricuspid pivot later year cardioband trial road
manag believ tricuspid patient undertr mitral regurgit
market size perspect hear mani call popul larger mr overal manag
believ lot work done lot optimist use
pascal cardioband eventu patient popul
surgic heart valv continu grow main question us post-low risk environ
patient get savr surgic aortic valv replac manag said primari factor
would anatomi access heart team age lifestyl patient prefer addit bia
occur center that surgeri assum savr would recommend
patient see clinician step away intervent cardiologist remind
call ew maintain underli target surgic structur heart
busi result driven solid growth ou partial off-set lower savr procedur
us due tavr adopt term impact low risk approv surgic busi
manag believ cannib market expans dynam histor
involv patient come sidelin new indic tavr accord
compani ew highlight inspiri resilia aortic surgic valv continu exhibit growth region
see good traction particularli among activ patient beyond major busi
aortic ew might see switch us surgeri could good growth driver emerg
market treatment much lower bottom line manag said surgic busi
continu see posit dollar growth
critic cc growth driven hemospher ew cc busi grew
underli includ driven strong perform across categori particular
strength us eu hemospher sale manag note hemospher predict
monitor technolog import driver strong perform out-performance also
reflect halo effect hospit custom look holist approach product suit ew
manag remain optimist cc pipelin continu invest busi although
capit intens manag also note cc segment gener solid posit
cash-flow continu hold global leadership posit call ew expect cc sale
come around top-end guidanc rang forecast cc sale total
year
manag expect remain focus current segment ask odd
multi-billion dollar deal ew manag agre chanc slim none compani
reiter focu remain structur heart diseas critic care ew continu
innov remain leader busi compani continu explor opportun
heart failur seem fulli commit space yet
price target
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
